Human Cancer Target-Signaling Pathway of KRAS

The activation of KRAS signaling is a multi-step process that requires proper KRAS post-translation, plasma membrane-localization and interaction with effector proteins.
In response to extracellular stimuli, the conversion from inactive RAS-GDP to active RAS-GTP further promotes the activation of various signaling pathways, which includes MAPK pathway, PI3K pathway and the Ral-GEFs pathway, among them the MAPK pathway is the best characterized.
RAS-GTP directly binds to RAF protein, recruiting RAF kinase family from cytoplasm to membranes, where they dimerize and become active.
The activated RAF subsequently carries out a chain of phosphorylation reactions to its downstream substrates, MEK and ERK, and propagates the growth signal.
In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.
Click for more: https://www.medicilon.com/platform/kras/